Table 5.
Published series on ECT in BCC (additional studies in unselected populations are available in Table S3).
| Author | Year | Study | No Pts | No of Tumours | BCC Subtype |
BCC Presentation | T Size (mm) | Drug | Route | CR (%) |
Re-ECT (%) | F-Up (mos) | Recurrence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clover [7] | 2020 | Randomised (ECT vs. surgery) |
52 | 69 | Nodular/Superficial/ Infiltrative/Morpheaform |
Primary | 1.7 cm2 (0.2–10) |
BLM | i.t. | 86 a | 12 | 60 | 5-year LDFS, 87% (5 recurrences) |
| Kis [9] | 2019 | Case series | 12 | 17 | n.r. | Primary: 3 Recurrent: 9 |
11 (3–43) | BLM | i.v./i.t. | 100 | 33 | 19 | n.r. |
| Campana [10] | 2017 | Case series | 84 | 185 | Superficial/Nodular/Infiltrative/Morpheaform | Primary/recurrent (L/LA/Mts) |
20 (5–267) |
BLM | i.v./i.t. | 50 a | 29 | 49 | 5-year LPFS, 70% |
| Ruggeri [10] | 2015 | Case report | 1 | 3 | n.r | Recurrent, multifocal | 4, 7, 8 | BLM | i.v. | 100 | 0 | 7 | no |
| Salwa [11] | 2014 | Case series | 3 | 3 | n.r. | Primary, periocular | 0.5–1 cm2 | BLM | i.t. | 100 | 0 | 5–8 | no |
| Gatti [12] | 2014 | Case report | 1 | 1 | n.r. | Recurrent | n.r. | BLM | i.v. | 100 | 0 | 12 | no |
| Kis [13] | 2012 | Case series | 3 b | 99 | Superficial/Nodular/Ulcerated/Plaque | primary/recurrent | 9 (3–22) | BLM | i.v. | 87 a | 33 | n.r. | n.r. |
| Fantini[14] | 2008 | Case report | 1 | 3/3/“multiple” | BCC with SCC differentiation | Metastatic | n.r. | BLM | i.t./i.v. | 100 | 0 | 8 | no |
| Glass [15] | 1997 | Case series | 20 | 54 | Nodular | Primary | 9 (4–21) | BLM | i.t. | 98 c | 10 | 18 | no |
| Glass [16] | 1996 | Case report | 2 | 6 | Superficial/ Nodular |
n.r. | n.r. | BLM | i.v. | 33 c | 0 | n.r. | n.r. |
Note: BLM, bleomycin; CDDP, cisplatin; CR, clearance rate; ECT, electrochemotherapy; i.t., intratumoural; i.v., intravenous; LDFS, local disease-free survival; LPFS, local progression-free survival; mos, months; n.e., not evaluable; n.r., not reported; SCC, squamous cell carcinoma. a Per-tumour assessment; b All patients had Gorlin–Goltz syndrome; c Per-patient assessment.